Ferring and Enteris to develop oral version of injectable peptide therapeutic
US based Enteris BioPharma Inc. licensed its oral drug delivery technologies to Swiss-based Ferring Pharmaceuticals AS in order to develop an oral formulation of one of Ferring's peptide-based therapeutics.
- Drug Delivery
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.